Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival

Ahmedin Jemal, Elizabeth M Ward, Christopher J Johnson, Kathleen A Cronin, Jiemin Ma, Blythe Ryerson, Angela Mariotto, Andrew J Lake, Reda Wilson, Recinda L Sherman, Robert N Anderson, S Jane Henley, Betsy A Kohler, Lynne Penberthy, Eric J Feuer, Hannah K Weir, Ahmedin Jemal, Elizabeth M Ward, Christopher J Johnson, Kathleen A Cronin, Jiemin Ma, Blythe Ryerson, Angela Mariotto, Andrew J Lake, Reda Wilson, Recinda L Sherman, Robert N Anderson, S Jane Henley, Betsy A Kohler, Lynne Penberthy, Eric J Feuer, Hannah K Weir

Abstract

Background: The American Cancer Society (ACS), the Centers for Disease Control and Prevention (CDC), the National Cancer Institute (NCI), and the North American Association of Central Cancer Registries (NAACCR) collaborate to provide annual updates on cancer occurrence and trends in the United States. This Annual Report highlights survival rates. Data were from the CDC- and NCI-funded population-based cancer registry programs and compiled by NAACCR. Trends in age-standardized incidence and death rates for all cancers combined and for the leading cancer types by sex were estimated by joinpoint analysis and expressed as annual percent change. We used relative survival ratios and adjusted relative risk of death after a diagnosis of cancer (hazard ratios [HRs]) using Cox regression model to examine changes or differences in survival over time and by sociodemographic factors.

Results: Overall cancer death rates from 2010 to 2014 decreased by 1.8% (95% confidence interval [CI] = -1.8 to -1.8) per year in men, by 1.4% (95% CI = -1.4 to -1.3) per year in women, and by 1.6% (95% CI = -2.0 to -1.3) per year in children. Death rates decreased for 11 of the 16 most common cancer types in men and for 13 of the 18 most common cancer types in women, including lung, colorectal, female breast, and prostate, whereas death rates increased for liver (men and women), pancreas (men), brain (men), and uterine cancers. In contrast, overall incidence rates from 2009 to 2013 decreased by 2.3% (95% CI = -3.1 to -1.4) per year in men but stabilized in women. For several but not all cancer types, survival statistically significantly improved over time for both early and late-stage diseases. Between 1975 and 1977, and 2006 and 2012, for example, five-year relative survival for distant-stage disease statistically significantly increased from 18.7% (95% CI = 16.9% to 20.6%) to 33.6% (95% CI = 32.2% to 35.0%) for female breast cancer but not for liver cancer (from 1.1%, 95% CI = 0.3% to 2.9%, to 2.3%, 95% CI = 1.6% to 3.2%). Survival varied by race/ethnicity and state. For example, the adjusted relative risk of death for all cancers combined was 33% (HR = 1.33, 95% CI = 1.32 to 1.34) higher in non-Hispanic blacks and 51% (HR = 1.51, 95% CI = 1.46 to 1.56) higher in non-Hispanic American Indian/Alaska Native compared with non-Hispanic whites.

Conclusions: Cancer death rates continue to decrease in the United States. However, progress in reducing death rates and improving survival is limited for several cancer types, underscoring the need for intensified efforts to discover new strategies for prevention, early detection, and treatment and to apply proven preventive measures broadly and equitably.

© The Author 2017. Published by Oxford University Press.

Figures

Figure 1.
Figure 1.
Trends in age-standardized incidence (1999–2013) and death rates (2000–2014) for all cancers combined by sex. Rates were age-standardized to the 2000 US standard population (19 age groups Census P25–1130). Scattered points were observed rates; lines were fitted rates according to Joinpoint regression. Incidence rates were delay-adjusted and covered 89% of the US population, and mortality covered the entire United States. Registries included for incidence: Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming. AAPC is the average annual percent change and is a weighted average of the annual percent change (APC) over the fixed interval (2009–2013 for incidence, 2010–2014 for mortality) using the underlying joinpoint model for the period of 1999 to 2013 for incidence and the period of 2000 to 2014 for mortality. Joinpoint models with up to two joinpoints are based on rates per 100 000 persons that are age-standardized to the 2000 US standard population (19 age groups Census P25–1130). Joinpoint Regression Program, version 4.2.0.2. June 2015, Statistical Research and Applications Branch, National Cancer Institute. *The APC or AAPC is statistically significantly different from 0 (two-sided t test, P < .05). AAPC = average annual percent change; APC = annual percent change.
Figure 2
Figure 2
Age-standardized incidence rates and recent trends (five years) for the most common cancers by sex. Rates were age-standardized to the 2000 US standard population (19 age groups Census P25–1130) and were delay-adjusted and covered 89% of the US population. Registries included in analyses: Alabama, Alaska, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Texas, Utah, Vermont, Washington, West Virginia, Wisconsin, and Wyoming. AAPC is the average annual percent change and is a weighted average of the annual percent change (APC) over the fixed interval (2009–2013) using the underlying joinpoint model for the period of 1999 to 2013. Joinpoint models with up to two joinpoints are based on rates per 100 000 persons that are age-standardized to the 2000 US standard population (19 age groups Census P25–1130). Joinpoint Regression Program, version 4.2.0.2. June 2015, Statistical Research and Applications Branch, National Cancer Institute. *The AAPC is statistically significantly different from 0 (two-sided t test or z test, P < .05). AAPC = average annual percent change.
Figure 3
Figure 3
Age-standardized death rates and recent trends (five years) for the most common cancers by sex. Rates were age-standardized to the 2000 US standard population (19 age groups Census P25–1130). AAPC is the average annual percent change and is a weighted average of the annual percent change (APC) over the fixed interval (2010–2014) using the underlying joinpoint model for the period of 2000 to 2014. Joinpoint models with up to two joinpoints are based on rates per 100 000 persons that are age-standardized to the 2000 US standard population (19 age groups Census P25–1130). Joinpoint Regression Program, version 4.2.0.2. June 2015, Statistical Research and Applications Branch, National Cancer Institute. *The AAPC is statistically significantly different from 0 (two-sided t test or z test, P < .05). AAPC = average annual percent change.
Figure 4
Figure 4
Changes in five-year relative survival by cancer site and race, all ages, SEER 9*, 1975–2012. Error bars represent 95% confidence intervals. *The SEER 9 registries are Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah. NOS = not otherwise specified; SEER = Surveillance, Epidemiology, and End Results.
Figure 5
Figure 5
Changes in five-year relative survival for select childhood cancers (0–14 years), SEER 9*, 1975–2012. Error bars represent 95% confidence intervals. *The SEER 9 registries are Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, and Utah. ALL = acute lymphoid leukemia; AML = acute myeloid leukemia; NHL = non-Hodgkin lymphoma; SEER = Surveillance, Epidemiology, and End Results.

References

    1. Wingo PA, Ries LA, Rosenberg HM, et al. Cancer incidence and mortality, 1973–1995: A report card for the U.S. Cancer. 1998;82(6):1197–1207.
    1. Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst. 1999;91(8):675–690.
    1. Ries LA, Wingo PA, Miller DS, et al. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer. 2000;88(10):2398–2424.
    1. Howe HL, Wingo PA, Thun MJ, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001;93(11):824–842.
    1. Edwards BK, Howe HL, Ries LA, et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on U.S. cancer burden. Cancer. 2002;94(10):2766–2792.
    1. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95(17):1276–1299.
    1. Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival. Cancer. 2004;101(1):3–27.
    1. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005;97(19):1407–1427.
    1. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006;107(8):1711–1742.
    1. Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007;110(10):2119–2152.
    1. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100(23):1672–1694.
    1. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116(3):544–573.
    1. Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975–2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst. 2011;103(9):714–736.
    1. Eheman C, Henley SJ, Ballard-Barbash R, et al. Annual report to the nation on the status of cancer, 1975–2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer. 2012;118(9):2338–2366.
    1. Jemal A, Simard EP, Dorell C, et al. Annual report to the nation on the status of cancer, 1975–2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst. 2013;105(3):175–201.
    1. Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120(9):1290–1314.
    1. Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107(6):XXX(X):XXX–XXX.
    1. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual report to the nation on the status of cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122(9):1312–1337.
    1. Measurement of progress against cancer. Extramural Committee to Assess Measures of Progress Against Cancer. J Natl Cancer Inst. 1990;82(10):825–835.
    1. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med. 2006;260(2):103–117.
    1. Croswell JM, Ransohoff DF, Kramer BS. Principles of cancer screening: Lessons from history and study design issues. Semin Oncol. 2010;37(3):202–215.
    1. North American Association of Central Cancer Registries. NAACCR data quality criteria. Available at . Accessed July 8, 2015.
    1. World Health Organization. International Classification of Diseases for Oncology. 3rd ed.Geneva, Switzerland: World Health Organization Press; 2000.
    1. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2012. Bethesda, MD: National Cancer Institute; 2015. . Accessed June 10, 2016.
    1. Young JL, Jr, Roffers SD, Ries LAG, et al. SEER Summary Staging Manual 2000: Codes and Coding Instructions. Bethesda, MD: National Cancer Institute; 2001.
    1. Clegg LX, Feuer EJ, Midthune DN, et al. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002;94(20):1537–1545.
    1. Kochanek KD, Murphy SL, Xu J, et al. Deaths: Final data for 2014. Natl Vital Stat Rep. 2016;65(4):1–122.
    1. Espey DK, Jim MA, Richards TB, et al. Methods for improving the quality and completeness of mortality data for American Indians and Alaska Natives. Am J Public Health. 2014;104(suppl 3):S286–S294.
    1. Espey DK, Wiggins CL, Jim MA, et al. Methods for improving cancer surveillance data in American Indian and Alaska Native populations. Cancer. 2008;113(5 suppl):1120–1130.
    1. Surveillance, Epidemiology, and End Results (SEER) Program, National Cancer Institute. Population estimates used in NCI's SEER*Stat software. . Accessed July 13, 2015.
    1. Centers for Disease Control and Prevention. National vital statistics system. . Accessed December 22, 2016.
    1. Ingram DD, Parker JD, Schenker N, et al. United States Census 2000 population with bridged race categories: Data evaluation and research. Vital Health Stat. 2003:2(135).
    1. Weir HK, Johnson CJ, Mariotto AB, et al. Evaluation of North American Association of Central Cancer Registries' (NAACCR) data for use in population-based cancer survival studies. J Natl Cancer Inst Monogr. 2014;2014(49):198–209.
    1. Rosso S, De Angelis R, Ciccolallo L, et al. Multiple tumours in survival estimates. Eur J Cancer. 2009;45(6):1080–1094.
    1. Surveillance Research Program, National Cancer Institute. SEER*Stat software version 8.3.2. . Accessed June 10, 2016.
    1. Tiwari RC, Clegg LX, Zou Z. Efficient interval estimation for age-adjusted cancer rates. Stat Methods Med Res. 2006;15(6):547–569.
    1. National Cancer Institute. Joinpoint regression program, version 4.2.0.2. 2015. . Accessed July 14, 2015.
    1. Kim HJ, Fay MP, Feuer EJ, et al. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000;19(3):335–351.
    1. Clegg LX, Hankey BF, Tiwari R, et al. Estimating average annual per cent change in trend analysis. Stat Med. 2009;28(29):3670–3682.
    1. National Cancer Institute. AAPC confidence intervals--Joinpoint Help System 4.3.1.0. . Accessed August 22, 2016.
    1. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer-Verlag; 2010.
    1. US Department of Health and Human Services. The Health Consequences of Smoking: 50 Years of Progress. A Report of the Surgeon General. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. Printed with corrections, January 2014.
    1. Jamal A, Homa DM, O'Connor E, et al. Current cigarette smoking among adults United States, 2005–2014. MMWR Morb Mortal Wkly Rep. 2015;64(44):1233–1240.
    1. Jacobs EJ, Newton CC, Carter BD, et al. What proportion of cancer deaths in the contemporary United States is attributable to cigarette smoking? Ann Epidemiol. 2015;25(3):179–182, e1.
    1. Lortet-Tieulent J, Goding Sauer A, Siegel RL, et al. State-level cancer mortality attributable to cigarette smoking in the United States. JAMA Intern Med. 2016;176(12):1792–1798.
    1. Siegel RL, Jacobs EJ, Newton CC, et al. Deaths due to cigarette smoking for 12 smoking-related cancers in the United States. JAMA Intern Med. 2015;175(9):1574–1576.
    1. Centers for Disease Control and Prevention. Best Practices for Comprehensive Tobacco Control Programs—2014. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014.
    1. Ward EM, Jemal A, Chen A. Increasing incidence of thyroid cancer: Is diagnostic scrutiny the sole explanation? Future Oncol. 2010;6(2):185–188.
    1. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol. 2011;65(5 suppl 1):S17–S25, e1–e3.
    1. Vaccarella S, Franceschi S, Bray F, et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med. 2016;375(7):614–617.
    1. Aschebrook-Kilfoy B, Grogan RH, Ward MH, et al. Follicular thyroid cancer incidence patterns in the United States, 1980–2009. Thyroid. 2013;23(8):1015–1021.
    1. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.
    1. Jemal A, Fedewa SA, Ma J, et al. Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA. 2015;314(19):2054–2061.
    1. Jemal A, Ma J, Siegel R, et al. Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. JAMA Oncol. 2016;2(12):1657–1660.
    1. Prasad SM, Drazer MW, Huo D, et al. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates. JAMA. 2012;307(16):1692–1694.
    1. US Preventive Services Task Force. Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185–191.
    1. World Cancer Research Fund American Institute for Cancer Research. Policy and Action for Cancer Prevention. Food, Nutrition, and Physical Activity: A Global Perspective. Washington, DC: AICR; 2009.
    1. Ross JA, Spector LG. Cancers in children. In: Schottenfeld D, Fraumeni JF. Jr, eds. Cancer Epidemiology and Prevention. 3rd ed.New York, NY: Oxford University Press; 2006:1251–1268.
    1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute; 2016. .
    1. Barrington-Trimis JL, Cockburn M, Metayer C, et al. Trends in childhood leukemia incidence over two decades from 1992 to 2013. Int J Cancer. 2017;140(5):1000–1008.
    1. Ward E, DeSantis C, Robbins A, et al. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83–103.
    1. Linet MS, Brown LM, Mbulaiteye SM, et al. International long-term trends and recent patterns in the incidence of leukemias and lymphomas among children and adolescents ages 0–19 years. Int J Cancer. 2016;138(8):1862–1874.
    1. Cho H, Mariotto AB, Schwartz LM, et al. When do changes in cancer survival mean progress? The insight from population incidence and mortality. J Natl Cancer Inst Monogr. 2014;2014(49):187–197.
    1. Loeb S, Bjurlin MA, Nicholson J, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol. 2014;65(6):1046–1055.
    1. Jani AB, Master VA, Rossi PJ, et al. Grade migration in prostate cancer: An analysis using the Surveillance, Epidemiology, and End Results registry. Prostate Cancer Prostatic Dis. 2007;10(4):347–351.
    1. Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: Interpreting trends in prostate cancer—part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999;91(12):1017–1024.
    1. Brawley OW. Trends in prostate cancer in the United States. J Natl Cancer Inst Monogr. 2012;2012(45):152–156.
    1. Etzioni R, Gulati R, Tsodikov A, et al. The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines. Cancer. 2012;118(23):5955–5963.
    1. Miller BA, Feuer EJ, Hankey BF. The increasing incidence of breast cancer since 1982: Relevance of early detection. Cancer Causes Control. 1991;2(2):67–74.
    1. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res. 2007;9(3):R28.
    1. Chen L, Linden HM, Anderson BO, et al. Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage. Breast Cancer Res Treat. 2014;147(3):609–616.
    1. Sledge GW, Mamounas EP, Hortobagyi GN, et al. Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014;32(19):1979–1986.
    1. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–1792.
    1. Swan J, Breen N, Graubard BI, et al. Data and trends in cancer screening in the United States: Results from the 2005 National Health Interview Survey. Cancer. 2010;116(20):4872–4881.
    1. Ciombor KK, Wu C, Goldberg RM. Recent therapeutic advances in the treatment of colorectal cancer. Annu Rev Med. 2015;66:83–95.
    1. Salem ME, Hartley M, Unger K, et al. Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction. Oncology (Williston Park). 2016;30(6):546–562.
    1. Hiatt RA, Klabunde C, Breen N, et al. Cancer screening practices from National Health Interview Surveys: Past, present, and future. J Natl Cancer Inst. 2002;94(24):1837–1846.
    1. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative mortality for high-risk surgery. N Engl J Med. 2011;364(22):2128–2137.
    1. Hunter T. Treatment for chronic myelogenous leukemia: The long road to imatinib. J Clin Invest. 2007;117(8):2036–2043.
    1. Dotan E, Aggarwal C, Smith MR. Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin's lymphoma. P T. 2010;35(3):148–157.
    1. DeVita VT, Jr, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366(23):2207–2214.
    1. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: Rationale and results. N Engl J Med. 1973;288(19):998–1006.
    1. Armstrong GT, Chen Y, Yasui Y, et al. Reduction in late mortality among 5-year survivors of childhood cancer. N Engl J Med. 2016;374(9):833–842.
    1. Children's Oncology Group. . Accessed January 4, 2017.
    1. Pennock GK, Chow LQ. The evolving role of immune checkpoint inhibitors in cancer treatment. Oncologist. 2015;20(7):812–822.
    1. Fedewa SA, Ward EM, Stewart AK, et al. Delays in adjuvant chemotherapy treatment among patients with breast cancer are more likely in African American and Hispanic populations: A national cohort study 2004–2006. J Clin Oncol. 2010;28(27):4135–4141.
    1. Griggs JJ, Hawley ST, Graff JJ, et al. Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol. 2012;30(25):3058–3064.
    1. Schmid M, Meyer CP, Reznor G, et al. Racial differences in the surgical care of Medicare beneficiaries with localized prostate cancer. JAMA Oncol. 2016;2(1):85–93.
    1. Wang EH, Yu JB, Abouassally R, et al. Disparities in treatment of patients with high-risk prostate cancer: Results from a population-based cohort. Urology. 2016;95:88–94.
    1. Warner ET, Tamimi RM, Hughes ME, et al. Racial and ethnic differences in breast cancer survival: Mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol. 2015;33(20):2254–2261.
    1. Hershman DL, Tsui J, Wright JD, et al. Household net worth, racial disparities, and hormonal therapy adherence among women with early-stage breast cancer. J Clin Oncol. 2015;33(9):1053–1059.
    1. Freedman RA, Virgo KS, He Y, et al. The association of race/ethnicity, insurance status, and socioeconomic factors with breast cancer care. Cancer. 2011;117(1):180–189.
    1. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–357.
    1. US Bureau of Labor Statistics. Labor force and characteristics by race and ethnicity, 2014. Report 1057. BLS Reports. 2015. .
    1. Pinheiro PS, Morris CR, Liu L, et al. The impact of follow-up type and missed deaths on population-based cancer survival studies for Hispanics and Asians. J Natl Cancer Inst Monogr. 2014;2014(49):210–217.
    1. Johnson CJ, Weir HK, Yin D, et al. The impact of patient follow-up on population-based survival rates. J Registry Manag. 2010;37(3):86–103.
    1. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8 suppl):IV–3–18.
    1. Feuer EJ, Lee M, Mariotto AB, et al. The Cancer Survival Query System: Making survival estimates from the Surveillance, Epidemiology, and End Results program more timely and relevant for recently diagnosed patients. Cancer. 2012;118(22):5652–5662.
    1. Feuer EJ, Rabin BA, Zou Z, et al. The Surveillance, Epidemiology, and End Results Cancer Survival Calculator SEER*CSC: Validation in a managed care setting. J Natl Cancer Inst Monogr. 2014;2014(49):265–274.
    1. Chen VW, Eheman CR, Johnson CJ, et al. Enhancing cancer registry data for comparative effectiveness research (CER) project: overview and methodology. J Registry Manag. 2014;41(3):103–112.
    1. Liebler CA, Halpern-Manners A. A practical approach to using multiple-race response data: A bridging method for public-use microdata. Demography. 2008;45(1):143–155.
    1. Arias E, Heron M, Hakes JK. The validity of race and Hispanic-origin reporting on death certificates in the United States: An update. National Center for Health Statistics. Vital Health Stat. 2016;2(172).
    1. Pinheiro PS, Sherman RL, Trapido EJ, et al. Cancer incidence in first generation US Hispanics: Cubans, Mexicans, Puerto Ricans, and new Latinos. Cancer Epidemiol Biomarkers Prev. 2009;18(8):2162–2169.
    1. Pinheiro PS, Sherman RL. Why an alternative algorithm for identification of Hispanic subgroups is useful. J Registry Manag. 2009;36(1):3–4.
    1. Lowy D, Singer D, DePinho R, et al. Cancer moonshot countdown. Nat Biotechnol. 2016;34(6):596–599.
    1. The Vice President's Cancer Moonshot. . Accessed August 19, 2016.
    1. Fojo T, Grady C. How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101(15):1044–1048.
    1. Kantarjian HM, Fojo T, Mathisen M, et al. Cancer drugs in the United States: Justum Pretium—the just price. J Clin Oncol. 2013;31(28):3600–3604.
    1. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med. 2011;364(21):2060–2065.
    1. Zafar SY, Abernethy AP. Financial toxicity, Part I: A new name for a growing problem. Oncology (Williston Park). 2013;27(2):80–81, 149.
    1. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143–1152.
    1. Ramsey SD, Bansal A, Fedorenko CR, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34(9):980–986.
    1. Schnipper LE, Davidson NE, Wollins DS, et al. American Society of Clinical Oncology statement: A conceptual framework to assess the value of cancer treatment options. J Clin Oncol. 2015;33(23):2563–2577.
    1. Aelion CM, Airhihenbuwa CO, Alemagno S, et al. The US Cancer Moonshot initiative. Lancet Oncol. 2016;17(5):e178–e180.
    1. Neugut AI, Gross CP. Targeting the Cancer Moonshot. JAMA Oncol. 2016;2(4):421–422.
    1. Thun MJ, Jemal A. How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tob Control. 2006;15(5):345–347.
    1. Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One. 2010;5(3):e9584.
    1. Jemal A, Thun M, Yu XQ, et al. Changes in smoking prevalence among US adults by state and region: Estimates from the Tobacco Use Supplement to the Current Population Survey, 1992–2007. BMC Public Health. 2011;11:512.
    1. Holmes CB, King BA, Babb SD. Stuck in neutral: Stalled progress in statewide comprehensive smoke-free laws and cigarette excise taxes, United States, 2000–2014. Prev Chronic Dis. 2016;13:E80.
    1. American Cancer Society Cancer Action Network. How do you measure up? A progress report on state legislative activity to reduce cancer incidence and mortality. 14th ed.American Cancer Society Cancer Action Network; 2016. . Accessed August 22, 2016.
    1. Fedewa SA, Sauer AG, Siegel RL, et al. Prevalence of major risk factors and use of screening tests for cancer in the United States. Cancer Epidemiol Biomarkers Prev. 2015;24(4):637–652.
    1. Doria-Rose VP, White MC, Klabunde CN, et al. Use of lung cancer screening tests in the United States: Results from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2012;21(7):1049–1059.
    1. Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(29):784–792.
    1. Jemal A, Fedewa SA. Prevalence of hepatitis C virus testing in cohorts born between 1945 and 1965 in the US Am J Prev Med. 2015;48(5):e7–e9.
    1. Ogden CL, Carroll MD, Lawman HG, et al. Trends in obesity prevalence among children and adolescents in the United States, 1988–1994 through 2013–2014. JAMA. 2016;315(21):2292–2299.
    1. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med. 2003;348(17):1625–1638.
    1. Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103(24):1827–1839.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren